Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Seeks Review Of Enbrel Ruling

Firm Petitions For En Banc Rehearing Of Etanercept Decision

Executive Summary

Sandoz is seeking an en banc rehearing of a recent appeals court decision that stands to keep its Erelzi biosimilar etanercept rival to Enbrel off the market until 2029 in the US, claiming that the ruling provides a “playbook” for originators to extend patents beyond their legitimate terms.

You may also be interested in...



US Biosimilars See A Banner Year Despite Few Approvals

With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.

Sandoz Sees Revolution In US Biosimilars Market

Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.

Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat

Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel